We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Game-Changing Endovascular Device-Based Approach Helps Patients Suffering From Heart Failure

By HospiMedica International staff writers
Posted on 24 Mar 2023

When there are changes in cardiac output, the baroreflex mechanism and baroreceptors react by stimulating the sympathetic system, leading to vasoconstriction and regulating heart rate and blood pressure to maintain homeostasis. However, in heart failure, the baroreflex becomes chronically impaired, causing excessive sympathetic activity and decreased parasympathetic activity, which ultimately overburdens the heart. For individuals with symptomatic heart failure who have already tried various medications without much improvement, a new percutaneous catheter-based therapy could potentially provide clinical relief.

The EVBA (endovascular baroreflex amplification) procedure using the unique MobiusHD device from Vascular Dynamics, Inc. (Irvine, CA, USA) stimulates the body's inherent mechanism to restore autonomic equilibrium and ease the heart's workload. The EVBA procedure involves the implantation of the MobiusHD device at a specific location within the carotid sinus. Prior to the procedure, imaging is conducted to pinpoint the optimal target site, and the entire process can be completed within 30 minutes on average.


Image: The percutaneous EVBA procedure allows for precise placement of the MobiusHD implant in the target location (Photo courtesy of Vascular Dynamics)
Image: The percutaneous EVBA procedure allows for precise placement of the MobiusHD implant in the target location (Photo courtesy of Vascular Dynamics)

By altering the shape of the carotid sinus to enhance local arterial wall stretch, the MobiusHD device induces mechanical stimulation of the arterial baroreceptor reflex. This, in turn, stimulates increased nerve signaling and triggers a reduction in sympathetic activity while augmenting parasympathetic activity, thereby rebalancing the autonomic nervous system. This modulation is believed to alleviate symptoms and slow the progression of HFrEF. As a result, the MobiusHD device may present a promising alternative solution for patients with symptomatic heart failure who have not responded well to traditional drug treatments.

A study evaluating the efficacy of the MobiusHD device in patients with progressive heart failure who remained symptomatic despite guideline-directed medical therapy recently presented two-year findings. The results revealed that the implantation of the device and its associated procedure led to continued enhancements in patient-centered outcomes, such as KCCQ scores, 6MWD, and NYHA class, alongside improvements in LVEF and NT-proBNP levels. These outcomes suggest that the EVBA procedure can offer a clinically meaningful and long-lasting benefit for certain heart failure patients.

Related Links:
Vascular Dynamics, Inc.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
EMG/NCV Testing Unit
Cadwell EMG/NCV/EP Sierra Summit Device

Latest Surgical Techniques News

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Soft, Flexible, Battery-Free Implant Continuously Monitors Bladder Function

AR Headset-Enhanced Abdominal Surgery Empower Surgeons to Perform More Efficient Procedures